You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Inetetamab

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Real-world Study of Inetetamab for First-line Treatment of MBC

Not yet recruiting
  • Breast Cancer
  • Real-world Study
  • Inetetamab
  • (no location specified)
Aug 6, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Recruiting
  • HER2-positive Advanced Breast Cancer
  • Inetetamab Combined With Pyrotinib and Vinorelbine
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 3, 2023

Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)

Recruiting
  • Breast Cancer
  • Inetetamab
  • +2 more
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023

Breast Cancer Trial in Xi'an (Inetetamab plus pyrotiniband and capecitabine)

Active, not recruiting
  • Breast Cancer
  • Inetetamab plus pyrotiniband and capecitabine
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

HER2-positive Recurrent/Metastatic Breast Cancer Trial (Inetetamab, pyrotinib, chemo)

Not yet recruiting
  • HER2-positive Recurrent/Metastatic Breast Cancer
  • Inetetamab, pyrotinib, chemotherapy
  • (no location specified)
Nov 16, 2022

Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)

Recruiting
  • Locally Advanced Breast Cancer
  • Chemotherapy Effect
  • inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 28, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line

Recruiting
  • Breast Neoplasms
  • Inetetamab
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Mar 16, 2023

HER2 Positive Metastatic Breast Cancer Trial in Zhengzhou (inetetamab and PD-1 inhibitor combined with chemo.)

Recruiting
  • HER2 Positive Metastatic Breast Cancer
  • inetetamab and PD-1 inhibitor combined with chemotherapy.
  • Zhengzhou, Henan, China
    Henan cancer hospital
Aug 2, 2022

Breast Cancer Trial in Beijing (Inetetamab, Toripalimab, Albumin-Bound Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Inetetamab
  • +2 more
  • Beijing, China
    Cancer Hospital Chinese Academy Of Medical Sciences
Mar 14, 2022

RWS of Inetetamab HER2 Positive Advanced Breast Cancer

Not yet recruiting
  • HER2-positive Advanced Breast Cancer
  • Inetetamab
  • (no location specified)
Jul 14, 2021

Metastatic Breast Cancer Trial (Pyrotinib, Vinorelbine, Inetetamab)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jul 11, 2021

NSCLC Trial in Guangzhou (inetetamab, Pytotinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 16, 2021

Breast Cancer Trial in Guangzhou (Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI)

Recruiting
  • Breast Cancer
  • Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
  • Guangzhou, Guangdong, China
    Shusen Wang
Jul 1, 2021

Breast Tumors Trial in Zhengzhou (Pyrotinib Maleate, Dalpiciclib Isethionate Tablets, Inetetamab)

Recruiting
  • Breast Neoplasms
  • Pyrotinib Maleate
  • +3 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 1, 2022

Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in

Recruiting
  • Breast Cancer
  • Zhejiang, Hangzhou, China
    China
Feb 13, 2022

Breast Cancer Trial in Beijing (Inetetamab, Rapamycin, Pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Inetetamab
  • +3 more
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Jan 31, 2021

HER2+ Breast Cancer Trial in Xi'an (Trastuzumab, Pertuzumab, Nab paclitaxel)

Recruiting
  • HER2+ Breast Cancer
  • Xi'an, Shaanxi, China
  • +1 more
Jun 20, 2022

Breast Cancer Trial in Guangzhou (Inetetamab, Pyrotinib, Capecitabine)

Recruiting
  • Breast Cancer
  • Inetetamab
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat Sen Memorial Hospital，Sun Yat sen University
Dec 18, 2020